Summary
3-Deazauridine (NSC 126849) is a structural analog of uridine that inhibits the biosynthesis of Cytidine-5′-Triphosphate by competitive inhibition of Cytidine Triphosphate synthetase which is considered to be the primary mode of action of this nucleoside analog. Despite a paucity of clinical attention given to this drug as a single agent, it has generated much enthusiasm as a biological response modulator because of its synergistic effect with a number of antitumor agents including Cytosine Arabinoside, 5-aza-2′-deoxycytidine, 5-azacytidine, thymidine and D-galactosamine, although only the cytosine arabinoside/3-Deazauridine combination has been explored clinically. In this paper, the current status of the drug and future perspectives will be discussed.
Similar content being viewed by others
References
Helman LJ, Slavik M: 3-Deazauridine (NSC 126849) Clinical brochure. Investigational Drug Branch, Cancer Therapy Evaluation Progrom, Division of Cancer Treatment, National Cancer Institute, February 1976
Von Hoff DD, Slavik M, Muggia FM: 5-Azacytidine — A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Int Med 85:237–245, 1976
Von Hoff DD, Slavik M: 5-Azacytidine — A new anticancer drug with significant activity in acute myeloblastic leukemia. Advances in Pharmacology and Chemotherapy 14:287–329, 1977
Slavik M: Pharmacodynamics of 6-Azauridine 2′-3′-5′ Triacetate with the special interest on new clinical indications, Ph.D. Dissertation Thesis, Czechoslovak Academy of Sciences, Prague, 1969
Welch AD, Handschumacher RE, Finch SC, Jaffe JJ, Cardoso SS, Calabresi P: A synopsis of recent investigations of 6-Azauridine (NSC-32074). Cancer Chemother Rep 9:39–46, 1960
Robins MJ, Currie BL: The synthesis of 3-Deazauridine-4-Hydroxyl-1-(NB-D-Ribopentaphosphate)-2-pyridone. Chem Comm 2:1547–1548, 1968
Bloch A, Dutschman G, Currie BL, Robins RK, Robins MJ: Preparation and biological activity of various 3-Deazapyrimidines and related nucleotides. J Med Chem 16:294–297, 1973
Wang MC, Bloch A: Studies on the mode of action of 3-Deazapyrimidines. I. Metabolism of 3-Deazauridine and 3-Deazacytidine in microbial and tumor cells. Biochem Pharmacol 21:1063–1073, 1972
Shannon WM, Arnett G, Schabel FM Jr: 3-Deazauridine: Inhibition of ribonucleic acid virus-induced cytopathogenic effects in vitro. Antimicrob Ag Chemother 2:159–163, 1972
Khare GP, Sidwell RW, Huffman JH, Tolman RL, Robins RK: Inhibition of RNA virus replication in vitro by 3-Deazacytidine and 3-Deazauridine. Proc Soc Exp Biol Med 140:880–884, 1972
Shannon WM, Brockman RW, Westbrook L, Shaddix S, Schabel FM: Inhibition of gross leukemia virus-induced plaque formation in XC cells by 3-Deazauridine. J Nat Cancer Inst 52:199–205, 1974
Brockman RW, Shaddix SC, Williams M, Nelson JA, Rose LM, Schabel FM Jr: The mechanism of action of 3-Deazauridine in tumor cells sensitive and resistant to Arabinosylcytosine. Annals New York Acad Sci 255:501–521, 1975
McPartland RP, Wang MC, Bloch A, Weinfeld H: Cytidine 5-Triphosphate Synthetase as a target for inhibition by the antitumor agent 3-Deazauridine. Cancer Res 34:3107–3111, 1974
Chabner BA, Hande KR, Drake JC: Ara-C metabolism: Implications for drug resistance and drug interactions. Bull Cancer (Paris) 66:89–92, 1979
Drake JC, Hande KR, Fuller RW, Chabner BA: Cytidine and deoxycytidylate deaminase inhibition by uridine analogs. Biochem Pharmacol 29:807–811, 1980
Belt JA, Welch AD: Transport of uridine and 6-Azauridine in human lymphoblastoid cells: Specificity for the uncharged 6-Azauridine molecule. Mol Pharm 23:153–158, 1983
Dahlig-Harley E, Paterson ARP, Robins MJ, Cass CE: Transport of uridine and 3-Deazauridine in cultured human lymphoblastoid cells. Cancer Res 44:161–165, 1984
Karle JM, Cysyk RL: 3-Deazauridine inhibition of de novo pyrimidine biosynthesis and uridine salvage in cultured L1210 cells. (Abstract) Proc Am Assoc Cancer Res 24:295, 1983
Rustum YM, Creaven PJ, Slocum HK: Biochemical and pharmacological studies of 3-Deazauridine with L1210 cells susceptible and resistant to cytosine arabinoside. In W Siegenthaler and R Luthy (eds): Current Chemotherapy. Amer Soc for Microb, Washington DC, 1978, pp 1118–1120
Cysyk RL, Gormley PE, D'Anna ME, Adamson RH: The disposition of 3-Deazauridine in mice. Drug Metab Dispos 6:125–132, 1978
Bloch A, Dutschman G, Grindey G, Simpson CL: Prevention by testosterone of the intestinal toxicity caused by the antitumor agent 3-Deazauridine. Cancer Res 34:1299–1303, 1974
NCI Investigational Drugs: Pharmaceutical Data, US Dept. of health and Human Services Public Health Service, National Institutes of health, pp 86–88, 1983
Benvenuto JA, Hall SW, Farquhar D, Stewart DS, Benjamin RS, Loo TL: Pharmacokinetics and disposition of 3-Deazauridine in humans. Cancer Res 39:349–352, 1979
Creaven PJ, Priore RL, Mittelman A, Bruno S, Henderson ES, Rustum YM, Solomon JK Phase I trial and pharmacokinetics of a daily x 5 schedule of 3-Deazauridine. Cancer Treat Rep 66:81–84, 1982
Stewart DJ, Benvenuto JA, Leavens M, Hall SW, Benjamin RS, Plunkett W, McCredie KB, Burgess MA, Loo TL: Penetration of 3-Deazauridine into human brain, intracerebral tumor, and cerebrospinal fluid. Cancer Res 39:4119–4122, 1979
Yap BS, McCredie KB, Keating MJ, Bodey GP, Freireich EJ: Phase I–II study of 3-Deazauridine in adults with acute leukemia. Cancer Treat Rep 65(5–6):521–524, 1981
Rivera G, Pratt CB: Phase I study of 3-Deazauridine (NSC 126849) in children with cancer. Clin Pharm Ther 25:244–245, 1979
3-Deazauridine Annual Report to the Food and Drug Administration, Investigational Drug Branch, NCI. April, 1982
Stewart DJ, McCredie KD, Barlogie B, Valdivieso M, Benjamin RS, Burgess MA, Bodey GP: Phase I study of 3-Deazauridine in the treatment of adults with solid tumors. Cancer Treat Rep 64:1295–1299, 1980
Wiemann MC, Cummings FJ, Kaplan HG, Calabresi P: Phase I evaluation of 24-hours infusions of 3-Deazauridine (NSC 126849) in patients with solid tumors. (Abstract) Proc Am Assoc Cancer Res 21:175, 1980
Bruno S, Creaven PJ, Ledesma E, Poster D, Yoon J, Mittelman A: Phase II study of 3-Deazauridine in advanced colorectal adenocarcinoma. Am J Clin Onc 5(1):69–71, 1982
Chabner B: Pharmacologic Principles of Cancer Treatment. WB Saunders, 1982, pp 387–401
Chu MY, Fischer GA: A proposed mechanism of action of 1-B-D Arabinofuranosylcytosine as an inhibitor of the growth of leukemic cells. Biochem Pharmacol 11:423–430, 1962
Muller WEG; Rational design of arabinosyl nucleosides as antitumor and antiviral agents. J Antibiot (Tokyo) 30 (Suppl): 104–120, 1977
Kufe DW, Major PP, Egan EM, Beardsley GP: Correlation of cytotoxicity with incorporation of Ara-C into DNA. J Biol Chem 255:8997–9000, 1980
Hawtrey AO, Scott-Burden T, Robertson G: Inhibition of glycoprotein and glycolipid synthesis in hamster embryo cells by Cytosine Arabinoside and Hydroxyurea. Nature 252:58–60, 1974
Mills-Yamamoto C, Lauzon GJ, Paterson ARP: Toxicity of combinations of Arabinosylcytosine and 3-Deazauridine toward neoplastic cells in culture. Biochem Pharmacol 27:181–186, 1978
Chalbot GG, Bouchard J, Momparler RL: Kinetics of deamination of 5-aza-2′-deoxycytidine and cytosine arabinoside by human liver cytidine deaminase and its inhibition by 3-Deazauridine, thymidine or uracil arabinoside. Biochem Pharmacol 32(7):1327–1328, 1983
Lauzon GJ, Yang SE, Paterson ARP: Cell cycle arrest as a basis of enhancement of 1-B-D-arabinofuranosylcytosine anabolism in human lymphoblastoid RPMI 6410 cells cultured with Deazauridine. Biochem Pharmacol 30(14):1889–1894, 1981
Jackson RC, Williams JC, Weber G: Enzyme patterndirected chemotherapy: Synergistic interaction of 3-Deazauridine with D-galactosamine. Cancer Treat Rep 60:835–843, 1976
Campbell J, Rustum Y: Synergistic interaction between 3-Deazauridine (DAUR) and Arabinosylcytosine (Ara-C) in mice bearing L1210. (Abstract) Proc Am Assoc Cancer Res 21:277, 1980
Paterson ARP, Jakobs ES, Lauzon GJ, Weinstein WM: Drug sequence — dependent toxicity and small bowel mucosal injury in mice treated with low doses of 3-Deazauridine and 1-B-D-arabinofuranosylcytosine. Cancer Res 39:2216–2219, 1979
Bloch A, Wang MC, Simpson CL: Prevention by testosterone of the intestinal toxicity caused by antitumor agent 3-Deazauridine. (Abstract) Proc Am Assoc Cancer Res 14:97, 1973
Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCreadie K: In vivo cellular kinetics and pharmacological studies of 1-B-D-arabinofuranosylcytosine and 3-Deazauridine chemotherapy for relapsing acute leukemia. Cancer Res 41:1227–1235, 1981
Creaven PJ, Rustum YM, Madajewicz S, Bakshi M, Karakousis C, Pontes JE, Takita H, Henderson ES, Solomon J: Initial clinical and pharmacologic studies of Cytosine Arabinoside (Ara-C) modulated by 3-Deazauridine (DAUR). (Abstract) Proc Am Soc Clin Oncol 2:30, 1983
Pliml J, Šorm F: Synthesis of 2′ deoxy-D-furanosyl-5-azacytosine. Colin Czech Chem Commun 29:2576–2578, 1964
Momparler RL, Gonzales FA: Effect of intravenous infusion of 5-Aza-2′-deoxycytidine on survival time of mice with L1210 leukemia. Cancer Res 38:2673–2678, 1978
Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin Kun-Tsan, Momparler LF: Phase I study on 5-Aza-2′-deoxycytidine in children with acute leukemia. Leukemia Res 5(6):453–462, 1981
Momparler RL, Derse D: Kinetics of phosphorylation of 5-Aza-2′-deoxycytidine by deoxycytidine kinase. Biochem Pharmacol 28:1443–1444, 1979
Veselý J, Čihák A, Šorm F: Association of decreased uridine and deoxycytidine kinase with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-Azacytidine and 5-Aza-2′-deoxycytidine. Cancer Res 30:2180–2186, 1970
Veselý J, Čihák A: Incorporation of a potent antileukemic agent, 5-Aza-2′-deoxycytidine, into DNA of Cells from leukemic mice. Cancer Res 37:3684–3689, 1977
Momparler RL, Veselý J, Momparler LF, Rivard GE: Synergistic action of 5-Aza-2′-deoxycytidine and 3-Deazauridine on L1210 leukemic cells and EMT 6 tumor cells. Cancer Res 39:3822–3827, 1979
Momparler RL, Wilson VL, Jones PA: Correlation of inhibition of DNA methylation by 5-Aza-2′-deoxycytidine and its antileukemic activity. Proc 13th Int Canc Congress 1793, 1982
Momparler RL, Fischer GA: Mammalian deoxynucleoside kinases. I. Deoxycytidine kinsase: purification, properties and kinetic studies with Cytosine Arabinoside. J Biol Chem 243:4298–4304, 1968
Momparler RL, Goodman J: In vitro cytotoxic and biochemical effect of 5-Aza-2′-deoxycytidine. Cancer Res 37:1636–1639, 1977
Momparler RL: Pharmacology of 5-Aza-2′-deoxycytidine. In Antimetabolites in Biochemistry, Biology and Medicine J Skoda and P Langen (eds): Pergamon Press, New York, 1979, p 33
Graham FL, Whitmore GF: The effect of 1-B-D-arabinofuranosylcytosine on growth, viability and DNA synthesis of mouse L-cells. Cancer Res 30:2627–2635, 1970
Chu MY, Fischer GA: The incorporation of 3-H-cytosine arabinoside and its effect on murine leukemic cells (L5178Y). Biochem Pharmacol 17:753–767, 1968
Jones PA, Taylor SM: Cellular differentiation, cytidine analogs, and DNA methylation. Cell 20:85–93, 1980
Šorm F, Pískala A, Čihák A, Veselý J: 5-Azacytidine, a new highly effective cancerostatic. Experientia 20:202–203, 1964
Haňka LJ, Evans JS, Mason DJ, Deitz A: Microbial production of 5-Azacytidine. I. Production and biological activity. Antimicrobial Agents Chemo pp 619–624, 1966
Chabner B: Pharmacologic Principles of Cancer Treatment. W.B. Saunders, 1982, pp 202–212
Veselý J, Čihák A, Šorm F: Biochemical mechanisms of drug resistance. IV. Development of resistance to 5-Azacytidine and simultaneous depression of pyrimidine metabolism in leukemic mice. Int J Cancer 2:639–646, 1967
Veselý J, Čihák A: 5-Azacytidine: mechanism of action and biological effects in mammalian cells. Pharm Ther 2:813–840, 1978
Grant S, Cadman E: Altered 5-Azacytidine metabolism following 3-Deazauridine treatment of L5178Y and human myeloblasts. Cancer Res 40:4000–4006, 1980
Li LH, Olin EJ, Buskirk HH, Reineke LM: Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res 30:2760–2769, 1970
Plagemann PGW, Behrens M, Abraham D: Metabolism and cytotoxicity of 5-Azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Cancer Res 38:2458–2466, 1978
Li ZR, Campbell J, Rustum YM: Effect of 3-Deazauridine on the metabolism, toxicity and antitumor activity of Azacytidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine. Cancer Treat Rep 67(6):547–554, 1983
Lee T, Karon MR: Inhibition of protein synthesis in 5-Azacytidine-treated HeLa cells. Biochem Pharmacol 25:1737–1742, 1976
Kaloušek F, Raška K, Jurovik M, et al.: Effect of 5-Azacytidine on the acceptor activity of sRNA. Colln Czech Chem Commun 31:1421–1424, 1966
Čihák A, Veselý H, Šorm F: Thymidine kinase and polyribosomal distribution in regenerating rat liver following 5-Azacytidine. Biochem Biophys Acta 166:277–279, 1968
Čihák A, Veselý J: Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-Azacytidine. Biochem Pharmacol 21:3257–3265, 1972
Lee T: Modification of tRNA by 5-Azacytidine in HeLa cells (Abstract). Proc Am Assoc Cancer Res 14:94, 1973
Weiss JW, Pitot HC: Inhibition of ribosomal precursor RNA maturation by 5-Azacytidine and 8-Azaguanine in Novikoff hepatoma cells. Arch Biochem Biophys 165:588–596, 1974
Doskočil J, Šorm F: The determination of 5-Azapyrimidines and their derivatives in bacterial RNA. FEBS Lett 2:30–32, 1974
Veselý J, Čihák A, Šorm F: Biochemical mechanism of drug resistance. VII. Inhibition of orotic acid metabolism by 5-Azacytidine in leukemic mice sensitive and resistant to 5-Azacytidine. Biochem Pharmacol 17:519–524, 1968).
Čihák A: Modulation of orotate phosphoribosyltransferase and orotidine 5′-phosphate decarboxylase activities in regenerating rat liver by 5-Azacytidine. Colln Czech Chem Commun 39:3782–3792, 1974
Lee SS, Giovanella BC, Stehlin Jr JS: Selective lethal effect of thymidine on human and mouse tumor cells. Cell Physiol 92:401–406, 1977
Ellims PH: Thymidine as an anticancer agent alone or in combination: A biochemical appraisal. Cancer Chemother Pharm 10:1–6, 1982
Jackson RC: The regulation of thymidylate biosynthesis in Novikoff hepatoma cells and the effects of Amethopterin, 5-Fluorodeoxyuridine, and 3-Deazauridine. J Biol Chem 253(20):7440–7446, 1978
Lowe JK, Grindey GB: Inhibition of growth rate and deoxynucleoside triphosphate concentrations in cultured leukemia L1210 cells. Molecular Pharmacol 12:177–184, 1976
Lockshin A, Giovanella BC, Mendoza JT, Stehlin JS: Biochemical and cytotoxic effects of thymidine (TdR) and 3-Deazauridine (DAUR) on human melanoma cells. (Abstract) Proc Am Assoc Cancer Res 23:4, 1982
Bjursell G, Reichard P: Effects of thymidine on deoxyribonucleoside triphosphate pools and deoxyribonucleic acid synthesis in Chinese Hamster Ovary cells. J Biol Chem 248(11):3901–3909, 1973
White A, Handler P, Smith EL: Principles of Biochemistry, McGraw-Hill Book Co, 1978, 33
Keppler DOR, Smith DF: Nucleotide contents of ascites hepatoma cells and their changes induced in D-galactosamine. Cancer Res 34:705–711, 1974
Keppler D, Decker K: Studies on the mechanism of galactosamine hepatitis. Accumulation of galactosamine-1-phosphate and its inhibition of UDP-glucose pyrophosphorylase. Eur J Biochem 10:219–225, 1969
Keppler DOR, Rudigier JFM, Bischoff E, Decker KFA: The trapping of uridine phosphate by D-galactosamine, D-glucosamine, and 2-deoxy-D-galactose: A study on the mechanism of galactosamine hepatitis. Eur J Biochem 17:246–253, 1970
Decker K, Keppler D, Pausch J: The regulation of pyrimidine nucleotide level and its role in experimental hepatitis. Adv Enzyme Reg 11:205–230, 1973
Keppler DOR, Pausch J, Decker K: Selective uridine triphosphate deficiency induced by D-galactosamine in liver and reversed by pyrimidine nucleotide precursors. Effect on ribonucleic acid synthesis. J Biol Chem 249:211–216, 1974
Talley RW, O'Bryan RM, Tucker WG, Loo RV: Clinical pharmacology and anti-tumor activity of Cytosine Arabinoside. Cancer 20(5):809–816, 1967
Frei E III, Schlossman S, Israel M: New approaches to the treatment of non-hodgkin's lymphoma. Cancer Treat Rep 61(6):1209–1217, 1977
Cadman E, Farber L, Berd D, Bertino J: Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites. Canc Treat Rep 61:1109–1116, 1977
Sweet DL, Golomb HM, Ultmann JE, Miller JB, Stein RS, Lester EP, Mintz URI, Bitran JD, Streuli RA, Daly K (RN), Roth NO (RN): Cyclophosphamide, Vincristine, Methotrexate with leucovorin rescue, and Cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Int Med 92:785–790, 1980
Early AP, Preisler HD, Slocum H, Rustum YM: A pilot study of high dose 1-B-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: Clinical response and pharmacology. Cancer Res 42:1587–1594, 1982
Takvorian T, Canellos GP: High-dose Cytosine Arabinoside (Ara-C) in advanced non-hodgkin's lymphoma and chronic myelogenous leukemia (CML). (Abstract) Proc Am Soc Clin Oncol 2:217, 1983
Ellims PH, Gan TE, Medley G: Cytidine triphosphate synthetase activity in lymphoproliferative disorders. Cancer Res 43:1432–1435, 1983
Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, Swaiminathan A, Fletcher WS, Moss SE, Manthei RW: Phase II study of 5-Azacytidine in solid tumors. Cancer Treat Rep 61(1):55–58, 1977
Plagemann PGW, Behrens M, Abraham D: Metabolism and cytotoxicity of 5-Azacytidine in cultured Novikoff rat hepatoma and P388 mouse leukemia cells and their enhancement by preincubation with pyrazofurin. Cancer Res 38:2458–2466, 1978
Ahmed NK, Welch AD: Some properties of uridinecytidine kinase from a human malignant lymphoma. Cancer Res 39:3102–3106, 1979
Williams JC, Weber G, Morris HP: Increased UDP kinase activity in rat and human hepatomas. Nature (Lond) 253:567–569, 1975
Weber G: Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes Memorial Lecture. Cancer Res 43: 3466–3492, 1983
Kizaki H, Williams JC, Morris HP, Weber G: Increased cytidine 5′-triphosphate synthetase activity in rat and human tumors. Cancer Res 40:3921–3927, 1980
Weber G, Burt ME, Jackson RC, Prajda N, Lui MS, Takeda E: Purine and pyrimidine enzymic programs and nucleotide pattern in sarcoma. Cancer Res 43:1019–1023, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moriconi, W.J., Slavik, M. & Taylor, S. 3-Deazauridine (NSC 126849): an interesting modulator of biochemical response. Invest New Drugs 4, 67–84 (1986). https://doi.org/10.1007/BF00172020
Issue Date:
DOI: https://doi.org/10.1007/BF00172020